Champions Oncology, Inc.: Form 10-Q for the period ended Jan 31, 2015
Filed with the SEC on Mar 17, 2015 and accepted by EDGAR at Mar 17, 2015, 17:25 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-01-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2014-11-01 to 2015-01-31 | $1.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2014-05-01 to 2015-01-31 | $3.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2014-11-01 to 2015-01-31 | −$3.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2014-05-01 to 2015-01-31 | −$10.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2014-11-01 to 2015-01-31 | $12.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2014-05-01 to 2015-01-31 | $27.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2014-11-01 to 2015-01-31 | −$2.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months2014-05-01 to 2015-01-31 | −$9.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2014-11-01 to 2015-01-31 | −$0.05 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2014-05-01 to 2015-01-31 | −$0.16 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2014-11-01 to 2015-01-31 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2014-05-01 to 2015-01-31 | −$0.14 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2014-11-01 to 2015-01-31 | 67,245,577 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2014-05-01 to 2015-01-31 | 67,243,142 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2014-05-01 to 2015-01-31 | −$7.6m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 9 months2014-05-01 to 2015-01-31 | $84.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2015-01-31 | $182.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2015-01-31 | $1.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2015-01-31 | $2.8m | us-gaap:Assets |
| Current liabilities | At period end2015-01-31 | $6.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2015-01-31 | $7.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2015-01-31 | −$4.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001144204-15-016811. Last ingested by Listed: Nov 10, 2026, 03:33 ET. Listed shows no prices and gives no investment advice.